Skip to main content

1 Result(s)

within Yu-xian Bai Remove this filter Cancer Research Remove this filter

and

  1. Article

    Open Access

    Famitinib versus placebo in the treatment of refractory metastatic colorectal cancer: a multicenter, randomized, double-blinded, placebo-controlled, phase II clinical trial

    Metastatic colorectal cancer (mCRC) patients with progressive disease after all available standard therapies need new medication for further treatment. Famitinib is a small-molecule multikinase inhibitor, with...

    Rui-Hua Xu, Lin Shen, Ke-Ming Wang, Gang Wu, Chun-Mei Shi… in Chinese Journal of Cancer (2017)

    Download PDF (1231 KB) View Article